Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomePreferred Shares IssuedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Change in Accured Expenses: 2013-2024

Historic Change in Accured Expenses for vTv Therapeutics (VTVT) over the last 12 years, with Dec 2024 value amounting to -$5.2 million.

  • vTv Therapeutics' Change in Accured Expenses rose 911.86% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 206.55%. This contributed to the annual value of -$5.2 million for FY2024, which is 278.05% down from last year.
  • Latest data reveals that vTv Therapeutics reported Change in Accured Expenses of -$5.2 million as of FY2024, which was down 278.05% from $2.9 million recorded in FY2023.
  • In the past 5 years, vTv Therapeutics' Change in Accured Expenses registered a high of $2.9 million during FY2023, and its lowest value of -$5.2 million during FY2024.
  • Its 3-year average for Change in Accured Expenses is -$1.0 million, with a median of -$856,000 in 2022.
  • In the last 5 years, vTv Therapeutics' Change in Accured Expenses soared by 442.17% in 2023 and then crashed by 278.05% in 2024.
  • Yearly analysis of 5 years shows vTv Therapeutics' Change in Accured Expenses stood at -$997,000 in 2020, then soared by 283.35% to $1.8 million in 2021, then tumbled by 146.83% to -$856,000 in 2022, then surged by 442.17% to $2.9 million in 2023, then slumped by 278.05% to -$5.2 million in 2024.